Trial Profile
A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Celltrion
- 21 Jun 2020 Results of pooled analysis of two phase three trials, assessing Safety Profile of Rituximab Biosimilar Ct-P10 in Follicular Lymphoma patients presented at the 25th Congress of the European Haematology Association
- 06 Nov 2019 Long term follow up results (40 months) released in the 61st Annual Meeting and Exposition of the American Society of Hematology
- 13 Feb 2019 Status changed from active, no longer recruiting to completed.